Innoviva Reports 20% Revenue Growth to $107.8 Million in Q3 2025

Innoviva, Inc. reported significant financial performance for the third quarter of 2025, with total revenue reaching $107.8 million, a 20% increase from $89.5 million in the same period last year. The company’s net income surged to $89.9 million, or $1.30 per share, compared to a mere $1.2 million, or $0.02 per share, in the prior year. This growth was primarily driven by a 5% increase in royalty revenue from GlaxoSmithKline (GSK), totaling $59.9 million, and a substantial rise in net product sales, which climbed 70% to $47.3 million, bolstered by strong performances from products like GIAPREZA® and XACDURO®.

In comparison to the previous fiscal period, Innoviva's financials showed marked improvement. The company’s total assets increased to $1.43 billion as of September 30, 2025, up from $1.30 billion at the end of 2024. Cash and cash equivalents also saw a significant rise, reaching $476.5 million, compared to $305 million at the end of the previous year. The company’s operating expenses rose to $41 million, up from $29.8 million, largely due to increased research and development costs associated with ongoing projects, including the development of zoliflodacin, which is currently under FDA review.

Strategically, Innoviva has made notable advancements, including the acquisition of a proprietary long-acting oral drug delivery platform from Lyndra Therapeutics for $10.2 million, with additional milestone payments contingent on future developments. The company also invested $15 million in a term loan to Armata Pharmaceuticals, which is focused on developing bacteriophage therapies. Furthermore, Innoviva launched ZEVTERA® in the U.S. in July 2025, expanding its product portfolio in critical care and infectious diseases.

Operationally, Innoviva reported a strong increase in product adoption rates, with U.S. net product sales for GIAPREZA® rising 39% and XACDURO® sales nearly doubling, reflecting the effectiveness of its commercialization strategies. The company’s equity and long-term investments also showed favorable changes in fair value, totaling $62.3 million for the quarter, compared to unfavorable changes of $35.2 million in the same quarter last year. As of September 30, 2025, Innoviva's employee headcount remained stable, supporting its operational needs as it continues to expand its market presence.

Looking ahead, Innoviva expressed optimism regarding its growth trajectory, particularly with the anticipated FDA decision on zoliflodacin expected by December 15, 2025. The company plans to leverage its strong cash position to support ongoing operations and strategic investments, including a newly authorized share repurchase program of up to $125 million. Innoviva's management remains focused on maximizing shareholder value through its diverse portfolio of healthcare assets and continued innovation in its product offerings.